Banco de Sabadell’s Boston Scientific BSX Stock Holding History

Banco de Sabadell’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,400	Closed	-$105K	–	83
2021 Q3	$105K	Hold	2,400	–	–	0.07%	80
2021 Q2	$104K	Sell	2,400 -2,930	-55%	-$123K	0.07%	106
2021 Q1	$206K	Hold	5,330	–	–	0.02%	211
2020 Q4	$190K	Buy	+5,330	New	+$192K	0.02%	236

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Banco de Sabadell's BSX Position: Q4 2021 in Review

Banco de Sabadell sold out of Boston Scientific (BSX) in Q4 2021, closing a stake of 2,400 shares — an estimated $105K sold.

Banco de Sabadell first reported a position in BSX in Q4 2020 and held it in 4 quarters. The position peaked at $206K in Q1 2021. 888 funds tracked by Wall St. Rank hold BSX as of Q4 2021.

Banco de Sabadell reported no remaining Boston Scientific position as of Q4 2021 after selling out during the quarter.
Banco de Sabadell sold 2,400 Boston Scientific shares in Q4 2021, an estimated $105K.
Banco de Sabadell first reported a position in Boston Scientific in Q4 2020 and held it in 4 quarters.
Banco de Sabadell's Boston Scientific position peaked at $206K in Q1 2021.
888 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2021.

Based on Banco de Sabadell's 13F filing for Q4 2021, filed 14 Feb 2022.